Description: Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Home Page: www.biofrontera-us.com
BFRI Technical Analysis
120 Presidential Way
Woburn,
MA
01801
United States
Phone:
781-245-1325
Officers
| Name | Title |
|---|---|
| Dr. Hermann Lubbert Ph.D. | Exec. Chairman & Pres |
| Ms. Erica L. Monaco CPA | CEO, COO, Treasurer & Sec. |
| Mr. Eugene Fredrick Leffler III | Chief Financial Officer |
| Ms. Erica F. Gates CPA, M.B.A. | Sr. Director of Fin. & Principal Accounting Officer |
| Ms. Alycia Torres | VP of Admin. |
| Mr. Daniel Hakansson J.D. | Gen. Counsel & Head of Compliance |
| Mr. Mark Baldyga | Head of Sales & Marketing |
| Mr. Jeff Holm | Head of Professional Relations & Commercial Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1282 |
| Price-to-Sales TTM: | 0.8579 |
| IPO Date: | 2021-10-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 69 |